Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGEN2373, Balstilimab, and Vaccines in Surgically Resectable Pancreatic Adenocarcinoma
NCT06782932Phase 2Recruiting
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- May 2025
- Primary completion
- Dec 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of AGEN2373 in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoints: Dose Limiting Toxicities at 1 month, Grade 3 or Higher study drug-related toxicities at 2 years and 1 more. Started May 2025; status: recruiting.
02
Drugs
AGEN2373
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06782932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06782932.